This is what ChatGPT says about TrofI'm sorry, but as of my knowledge cutoff of September 2021, Trofinetide had not yet received FDA approval for the treatment of Rett syndrome or any other indication.
However, it is important to note that clinical trials for Trofinetide have shown promising results, and the drug has been granted Fast Track designation by the FDA for the treatment of Rett syndrome, which can expedite the development and review process.
It is possible that there may have been updates on Trofinetide's FDA approval status since my knowledge cutoff, so I suggest checking reliable news sources or contacting Neuren Pharmaceuticals, the company developing the drug, for the latest information.
Any doubts get out., page-32
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.94 |
Change
-0.040(0.20%) |
Mkt cap ! $2.548B | |||
| Open | High | Low | Value | Volume |
| $19.92 | $20.04 | $19.51 | $4.745M | 239.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 198 | $19.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.94 | 1256 | 2 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |